Understanding MASLD: Causes, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease

Introduction

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously referred to as non-alcoholic fatty liver disease (NAFLD), has emerged as the most prevalent cause of chronic liver disease worldwide [1]. Current epidemiological evaluations indicate that steatotic liver disease affects approximately 30 percent or more of the global adult population, driven primarily by rising rates of obesity and type 2 diabetes [2], [3]. MASLD is characterized by the accumulation of excess fat within hepatocytes (hepatic steatosis) in the presence of systemic metabolic dysregulation.

Although early stages involving simple fat accumulation can remain indolent for decades, a subset of individuals develops progressive hepatic inflammation, tissue injury, and scarring. Understanding the metabolic drivers of MASLD, recognizing associated risks, and implementing evidence-based clinical and lifestyle interventions are essential for preventing advanced fibrosis, liver failure, and extrahepatic complications [4].

The Transition from NAFLD to MASLD

In 2023, major international liver societies updated the nomenclature from NAFLD to MASLD through a global Delphi consensus process [5], [6]. The previous terminology relied on an exclusionary definition—namely, confirming the absence of significant alcohol intake. In contrast, the updated framework provides an affirmative, pathophysiologic definition centered on metabolic dysfunction while avoiding stigmatizing terminology [7].

Under current diagnostic criteria, a diagnosis of MASLD requires evidence of hepatic steatosis alongside at least one of five core cardiometabolic risk factors [5]:

• Increased adiposity: Elevated body mass index (BMI) or increased waist circumference based on population-adjusted thresholds.
• Dysglycemia: Impaired fasting glucose, elevated hemoglobin A1c, or established type 2 diabetes.
• Hypertension: Elevated resting blood pressure or active treatment with antihypertensive medication.
• Hypertriglyceridemia: Elevated serum triglycerides or specific lipid-lowering therapy.
• Low HDL cholesterol: Reduced levels of high-density lipoprotein cholesterol.

The revised classification also introduced the category MetALD to describe individuals who meet cardiometabolic criteria for MASLD but also consume moderate amounts of alcohol (20 to 50 grams daily for females and 30 to 60 grams daily for males) [7].

Pathophysiology: Lipid Dysregulation and Disease Stages

The core mechanism driving MASLD is an imbalance in hepatic lipid homeostasis. Under conditions of systemic insulin resistance and adipose tissue dysfunction, an excessive influx of non-esterified fatty acids reaches the liver [8], [9]. Coupled with elevated de novo lipogenesis and impaired mitochondrial fatty acid beta-oxidation, triglycerides accumulate within hepatocytes, establishing steatosis [10], [9].

The spectrum of disease progression includes:

• Simple Steatosis: Hepatic fat accumulation without active cellular injury or progressive inflammation.
• MASH (Metabolic Dysfunction-Associated Steatohepatitis): Ongoing lipid accumulation promotes lipotoxicity, cellular ballooning, oxidative stress, and necroinflammation [10].
• Fibrosis: Chronic inflammation triggers hepatic stellate cells to deposit excessive extracellular matrix proteins, leading to progressive structural scarring [2].
• Cirrhosis and End-Stage Liver Disease: Extensive architectural distortion and vascular compromise. Severe cirrhosis occurs in an estimated 3 to 5 percent of patients with MASLD, often evolving over several decades [4]. Advanced fibrosis also increases the risk of primary hepatocellular carcinoma [11].

Clinical Presentation and Systemic Complications

MASLD is characteristically asymptomatic during its early and intermediate stages. When symptoms manifest, patients frequently report non-specific complaints such as chronic fatigue, daytime sleepiness, or mild discomfort in the right upper quadrant of the abdomen. Consequently, the disease is often detected incidentally during evaluation of unrelated medical conditions or routine metabolic screening.

Importantly, MASLD is not solely an organ-specific liver disorder; it represents the hepatic manifestation of multisystem metabolic disease. Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in individuals with MASLD [1], [12]. Large-scale longitudinal cohort evaluations have demonstrated an increased relative hazard of composite cardiovascular events, including myocardial infarction, ischemic stroke, and heart failure, among individuals with MASLD compared to those without the condition [12]. Furthermore, MASLD is independently associated with an elevated incidence of chronic kidney disease and extrahepatic malignancies [5], [11].

Diagnostic Evaluation and Fibrosis Staging

Routine serum liver transaminases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) frequently remain within normal laboratory reference ranges, even in advanced steatohepatitis or significant fibrosis. Therefore, a comprehensive diagnostic approach incorporates clinical scoring and specialized imaging [13].

Non-Invasive Biomarker Panels

Validated non-invasive serum algorithms, most notably the Fibrosis-4 (FIB-4) index, are utilized in primary care and outpatient settings to stratify patients based on their probability of advanced fibrosis [1], [13]. Calculated from age, platelet count, ALT, and AST, a low FIB-4 score carries a high negative predictive value, ruling out advanced scarring in most patients and allowing safe ongoing monitoring in primary care [1].

Elastography and Advanced Imaging

When serum scores indicate indeterminate or elevated fibrosis risk, secondary risk assessment is performed using non-invasive imaging techniques [2]. Vibration-controlled transient elastography (VCTE) measures liver stiffness in kilopascals (kPa) to estimate fibrosis severity, while controlled attenuation parameter (CAP) scores quantify hepatic steatosis. Magnetic resonance elastography (MRE) and MRI proton density fat fraction (MRI-PDFF) offer high diagnostic precision in complex clinical scenarios.

Histopathologic Assessment

Percutaneous liver biopsy remains the definitive reference standard for diagnosing MASH and staging fibrosis [13]. However, because biopsy is invasive and carries risks of pain and rare bleeding, its clinical utility is primarily restricted to diagnostic uncertainty, conflicting non-invasive test results, or evaluation within randomized clinical trials [13].

Evidence-Based Management and Therapeutic Strategies

The foundational management of MASLD centers on lifestyle intervention, metabolic optimization, and cardiovascular risk reduction [1], [8].

Targeted Weight Loss and Dietary Modifications

Gradual, sustained weight reduction directly reduces hepatic fat accumulation, decreases necroinflammation, and promotes fibrosis regression [8]. Clinical evidence supports the following thresholds:

• A loss of 3 to 5 percent of total body weight generally produces a meaningful reduction in hepatic steatosis.
• A loss of 7 to 10 percent or greater is typically required to induce resolution of steatohepatitis and facilitate the stabilization or regression of hepatic fibrosis [8].

Nutritional patterns emphasizing whole foods—particularly the Mediterranean dietary model—provide therapeutic benefit [14]. Key principles include prioritizing monounsaturated and omega-3 fatty acids, increasing dietary fiber through vegetables and legumes, and strictly minimizing sugar-sweetened beverages and foods rich in added fructose, which directly stimulate hepatic de novo lipogenesis [9].

Physical Activity and Structured Exercise

Regular physical activity improves peripheral insulin sensitivity, reduces visceral adipose tissue, and lowers liver fat content even in the absence of significant body weight loss [15]. Clinical guidelines recommend at least 150 minutes of moderate-intensity aerobic exercise per week, combined with progressive resistance training. Managing and preventing sarcopenia (loss of skeletal muscle mass and strength) is also an important clinical consideration, as sarcopenia is linked to poorer metabolic and hepatic outcomes [1].

Cardiometabolic Pharmacotherapy

While historically no medications carried specific primary regulatory approvals for MASLD, medical management focuses on treating co-existing metabolic conditions using agents with hepatic benefits [1], [8]:

• Incretin Mimetics (GLP-1 Receptor Agonists): Glucagon-like peptide-1 receptor agonists, utilized for type 2 diabetes and chronic weight management, consistently improve metabolic parameters, reduce liver fat, and have demonstrated histological improvements in steatohepatitis in clinical trials [15], [8].
• SGLT2 Inhibitors: Sodium-glucose cotransporter-2 inhibitors reduce body weight, lower blood glucose, and improve liver enzyme profiles and hepatic steatosis markers in patients with type 2 diabetes [15].
• Targeted MASH Pharmacotherapies: The drug development pipeline is actively expanding, with liver-directed agents (such as thyroid hormone receptor-beta agonists and metabolic pathway modulators) under active clinical investigation and emerging into clinical practice for non-cirrhotic MASH with significant fibrosis [2], [8].

When to Refer to Specialist Care

Effective management of MASLD requires collaborative care pathways between primary care practitioners and liver specialists [1], [2]. Patients with low risk of fibrosis are optimally managed in primary care with focus on lifestyle changes and cardiovascular risk reduction. Immediate referral to a gastroenterologist or hepatologist is indicated when non-invasive tests (such as an indeterminate or high FIB-4 score or elevated transient elastography reading) suggest compensated advanced chronic liver disease, in cases of diagnostic ambiguity, or when signs of cirrhosis and portal hypertension are present [1], [2].

Medical Disclaimer

This article is provided solely for educational and informational purposes and does not constitute medical advice, diagnosis, or individualized treatment recommendations. Individuals with suspected or diagnosed liver disease should consult a qualified physician or healthcare provider to develop an appropriate, personalized management plan based on their specific clinical circumstances.

References

• Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review. Journal of Obesity & Metabolic Syndrome. 2023;32(3):197-213. View on PubMed
• Israelsen M, Francque S, Tsochatzis EA, Krag A. Steatotic liver disease. Lancet. 2024;404(10464):1751-1764. View on PubMed
• Miao L, Targher G, Byrne CD, Cao YY, Zheng MH. Current status and future trends of the global burden of MASLD. Trends in Endocrinology and Metabolism. 2024;35(8):697-709. View on PubMed
• Hagström H, Shang Y, Hegmar H, Nasr P. Natural history and progression of metabolic dysfunction-associated steatotic liver disease. The Lancet Gastroenterology & Hepatology. 2024;9(11):1026-1036. View on PubMed
• Bilson J, Mantovani A, Byrne CD, Targher G. Steatotic liver disease, MASLD and risk of chronic kidney disease. Diabetes & Metabolism. 2024;50(2):101519. View on PubMed
• Kanwal F, Neuschwander-Tetri BA, Loomba R, Rinella ME. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology. 2024;79(5):1216-1220. View on PubMed
• Kalligeros M, Vassilopoulos A, Vassilopoulos S, Victor DW, Mylonakis E, Noureddin M. Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020. Clinical Gastroenterology and Hepatology. 2024;22(5):1121-1123.e1. View on PubMed
• Zeng J, Fan JG, Francque SM. Therapeutic management of metabolic dysfunction associated steatotic liver disease. United European Gastroenterology Journal. 2024;12(1):47-58. View on PubMed
• Feng X, Zhang R, Yang Z, Zhang K, Xing J. Mechanism of Metabolic Dysfunction-associated Steatotic Liver Disease: Important role of lipid metabolism. Journal of Clinical and Translational Hepatology. 2024;12(10):890-901. View on PubMed
• Syed-Abdul MM. Lipid Metabolism in Metabolic-Associated Steatotic Liver Disease (MASLD). Metabolites. 2023;14(1):21. View on PubMed
• Kalligeros M, Henry L, Younossi ZM. Metabolic dysfunction-associated steatotic liver disease and its link to cancer. Metabolism. 2024;159:155977. View on PubMed
• Lee HH, Lee HA, Kim EJ, Kim HY, Kim HC, Ahn SH, Lee H, Kim SU. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Gut. 2024;73(7):1199-1206. View on PubMed
• Abdelhameed F, Kite C, Lagojda L, Dallaway A, Chatha KK, Chaggar SS, Dalamaga M, Kassi E, Kyrou I, Randeva HS. Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD. Current Obesity Reports. 2024;13(3):399-418. View on PubMed
• Benedé-Ubieto R, Cubero FJ, Nevzorova YA. Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD). Gut Microbes. 2024;16(1):2323789. View on PubMed
• Yanai H, Adachi H, Hakoshima M, Iida S, Katsuyama H. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments. International Journal of Molecular Sciences. 2023;24(20):15473. View on PubMed